Health Affairs notes that federal Office of the Inspector General studies “have repeatedly shown that Medicare’s reimbursement methodology for {certain} infusion drugs has resulted in payment amounts that bear little relationship to actual market prices.”

To read the Health Affairs article, please hit this link.